Low plasma Homoarginine (cas 156-86-5) concentration is associated with high rates of all-cause mortality in renal transplant recipients

Add time:09/29/2019    Source:infona.pl

In renal transplant recipients (RTR), we recently found that low urinary excretion of Homoarginine (cas 156-86-5) (hArg) is associated with mortality and graft failure. However, it is not known whether such prospective associations also hold true for plasma concentrations of hArg. In the present study, we therefore determined plasma concentrations of hArg in the same cohort, i.e. in 687 RTR (functioning graft ≥1 year), and in 140 healthy donors, before and after kidney donation. Plasma hArg concentrations were significantly lower in RTR compared to healthy controls [1.24 (0.95–1.63) µM vs. 1.58 (1.31–2.03) µM, P < 0.001], and kidney donation resulted in a decrease in plasma hArg concentration to 1.41 (1.10–1.81) µM (P < 0.001). In RTR, multivariable linear regression analysis revealed BMI (β = 0.124), heart rate (β = −0.091), pre-emptive transplantation (β = 0.078), antidiabetic medication (β = −0.091), eGFR (β = 0.272), plasma PTH (β = −0.098), uric acid (β = 0.137), alkaline phosphatase (β = −0.100), HDL (β = −0.111), NT-pro-BNP (β = −0.166), and urinary urea excretion (β = 0.139) as main determinants of plasma hArg (all P < 0.05). In RTR, plasma hArg concentration was inversely associated with all-cause [hazard ratio (HR) 0.59 (95% CI 0.50–0.70), P < 0.001] and cardiovascular mortality [HR 0.50 (0.39–0.66), P < 0.001], both expressed per standard deviation change in log-transformed hArg, independent of potential confounders. To conclude, our results suggest that the kidney is a major hArg production site and an important modulator of hArg homeostasis in the renal and cardiovascular systems. Moreover, low plasma hArg is independently associated with increased risk of cardiovascular mortality in RTR, which corroborates the cardiovascular importance of preserving kidney function after transplantation.

We also recommend Trading Suppliers and Manufacturers of Homoarginine (cas 156-86-5). Pls Click Website Link as below: cas 156-86-5 suppliers

Prev:Comprehensive analysis of the l-arginine/l-Homoarginine (cas 156-86-5)/nitric oxide pathway in preterm neonates: potential roles for Homoarginine (cas 156-86-5) and asymmetric dimethylarginine in foetal growth
Next:The role of l-arginine/l-Homoarginine (cas 156-86-5)/nitric oxide pathway for aortic distensibility and intima-media thickness in stroke patients)